Requiring FDA Guidances Does Not Always Advance The Science, Gene Therapy Director Says

OTAT Director Wilson Bryan says important cell and gene therapy guidances came from clear community needs, not user fee program requirements.

Cell therapy
The FDA's infusion of user fee capital for cell and gene therapy work likely will take years to create an impact. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies